Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia-Reference-Cited by-同舟云学术

Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia

Published:2024-06-17 Issue:7 Volume:54 Page:1214-1218
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Chee Lynette¹²^ORCID,Lee Nora¹³,Grigg Andrew⁴^ORCID,Chen Melissa⁵⁶,Schwarer Anthony⁶,Szer Jeff¹²^ORCID,Ratnasingam Sumita⁷,Raj Sonia⁸,Lukito Pohan⁹,Yeung David¹⁰¹¹,Hughes Timothy¹⁰¹¹,Shanmuganathan Naranie¹⁰¹¹

Affiliation:

1. Department of Clinical Haematology The Royal Melbourne Hospital and Peter MacCallum Cancer Centre Melbourne Victoria Australia

2. Department of Medicine The University of Melbourne Melbourne Victoria Australia

3. Bendigo Cancer Centre Bendigo Hospital Bendigo Victoria Australia

4. Department of Clinical Haematology Austin Health Melbourne Victoria Australia

5. Monash Haematology Monash Health Melbourne Victoria Australia

6. Department of Haematology Box Hill Hospital Melbourne Victoria Australia

7. Department of Haematology University Hospital Geelong Geelong Victoria Australia

8. Department of Haematology Royal Hobart Hospital Hobart Tasmania Australia

9. Ballarat Cancer Care and Haematology Ballarat Victoria Australia

10. Department of Haematology Royal Adelaide Hospital and SA Pathology Adelaide South Australia Australia

11. South Australian Health and Medical Research Institute, SAHMRI Adelaide South Australia Australia

Abstract

AbstractAsciminib is a novel allosteric STAMP (specifically targets the ABL myristoyl pocket) inhibitor of the BCR::ABL1 oncogene. Real‐world clinical outcomes of patients with tyrosine kinase inhibitor (TKI)‐resistant/intolerant chronic myeloid leukaemia (CML) in Australia on the Managed Access Programme for asciminib showed higher molecular responses for those with intolerance versus resistance ± intolerance to their last TKI. There remains a clinical need to improve outcomes in patients with CML who have resistance to multiple TKIs, especially in the ponatinib‐pretreated cohort.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.16446

Reference16 articles.

1. STI571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy

2. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

3. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

4. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

5. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia